Celltrion Presents the Long-Term Data for CT-P13 (Biosimilar, Infliximab) to Treat Inflammatory Bowel Disease (IBD) at ECCO 2024
Shots:
- The company presented 2yrs. results from the P-III (LIBERTY-CD) & (LIBERTY-UC) trial evaluating the superiority in safety & efficacy of CT-P13 (SC) vs Remicade in patients (n=180 & 237) with moderately to severely active CD & UC
- In the trials, 85.6% & 87% of patients completed the extension phase with clinical remission, clinical response, endoscopic remission, endoscopic response & corticosteroid-free remission maintained at wk.102 vs wk.54
- The company also presented a post hoc analysis evaluating the pattern of endoscopic mucosal healing across intestinal segments in patients enrolled in the P-III (LIBERTY-CD) trial. The results showed a significantly higher rate of endoscopic complete mucosal healing & partial mucosal healing with CT-P13 vs PBO
Ref: Businesswire | Image: Celltrion
Related News:- Celltrion’s Zymfentra (Infliximab-Dyyb) Receives the US FDA’s Approval for the Treatment of Inflammatory Bowel Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
